# Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

> **NCT02824003** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ISIS-GCGRRx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02824003
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-12-15
- **Final completion:** 2017-05-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824003, "Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02824003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*